am 251 has been researched along with Irritable Bowel Syndrome in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, CC | 1 |
| Yan, XJ | 1 |
| Chen, X | 1 |
| Wang, EM | 1 |
| Liu, Q | 1 |
| Zhang, LY | 1 |
| Chen, J | 1 |
| Fang, JY | 1 |
| Chen, SL | 1 |
1 other study available for am 251 and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats.
Topics: Adult; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonists; Endocannabinoids; Female; Human | 2014 |